Market news

NeoGenomics stock reaction to precision oncology expansion plan NeoGenomics (NEO) drew investor attention after executives detailed plans to expand in community-based precision oncology, highlighting next-generation sequencing, minimal residual disease testing, and workflow tools for community physicians as key focus areas. NeoGenomics shares have been on a strong run recently, with a 30-day share price return of 14.31% and a 90-day gain of 69.22%. The 1-year total shareholder return of...

Earlier in 2026, NeoGenomics executives detailed plans to expand in community-based precision oncology, with a particular push into next-generation sequencing, minimal residual disease testing, and workflow tools for community oncologists. An important takeaway is that NGS already represents a relatively small share of test volume but a much larger portion of clinical revenue, underscoring how mix shift toward advanced assays could reshape the company’s earnings profile. We’ll now examine...

NeoGenomics (NASDAQ:NEO) executives outlined the company’s strategy to expand its role in community-based precision oncology, emphasizing growth in next-generation sequencing, minimal residual disease testing and workflow tools designed for physicians treating patients closer to home. Speaking at t

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at NeoGenomics (NASDAQ:NEO) and its peers.

FORT MYERS, Fla., September 01, 2026--NeoGenomics will participate in the Morgan Stanley 24th Annual Global Healthcare Conference, Sept. 14–16, 2026, in New York.

Detailed price information for Neogenomics Inc (NEO-Q) from The Globe and Mail including charting and trades.

NeoGenomics (NEO) is a leading cancer genetics diagnostics lab. Its stock recently hit a new 2-year high. Shares are up more than 170% over the past 52 weeks. NEO maintains a 100% “Buy” technical opinion from Barchart. Analyst sentiment is predominantly bullish, with consensus price targets up to $35 and...

FORT MYERS, Fla., August 26, 2026--NeoGenomics announced expanded MolDX coverage for its RaDaR® ST MRD assay for immunotherapy monitoring in late-stage solid tumors.

Earnings, drug development, and healthcare reimbursement fueled the stock rallies.

Detailed price information for Neogenomics Inc (NEO-Q) from The Globe and Mail including charting and trades.

NeoGenomics (NEO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

NeoGenomics (NEO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

NeoGenomics (NEO) is back in focus after second quarter earnings on 28 July 2026 reported quarterly profitability, revenue of US$201.66 million, and updated full year guidance that raised revenue expectations and narrowed projected net loss. See our latest analysis for NeoGenomics. NeoGenomics shares traded at US$15.84 on 31 July 2026, with a 90 day share price return of 78.18% and a 1 year total shareholder return of 181.85%, which points to strong recent momentum despite a weaker 5 year...

Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) jumped 15.8% in the afternoon session after the company reported second-quarter 2026 earnings that surpassed Wall Street expectations and raised its full-year financial guidance.

Detailed price information for Neogenomics Inc (NEO-Q) from The Globe and Mail including charting and trades.

NeoGenomics Inc (NEO) reports robust revenue growth and margin expansion, while addressing challenges in its pharma segment and raising full-year guidance.

NeoGenomics (NEO) has an average rating of overweight and mean price target of $18.83, according to

FORT MYERS, Fla., July 28, 2026--NeoGenomics announced its second-quarter results for the period ended June 30, 2026.

NeoGenomics (NEO) reported Q2 adjusted earnings late Tuesday of $0.05 per diluted share, up from $0.

Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 11.2% year on year to $201.7 million. The company expects the full year’s revenue to be around $804 million, close to analysts’ estimates. Its non-GAAP profit of $0.05 per share was $0.02 above analysts’ consensus estimates.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

NeoGenomics (NASDAQ:NEO) raised its full-year 2026 revenue and adjusted EBITDA guidance after reporting second-quarter revenue growth that exceeded its prior outlook, led by higher-value clinical testing and continued expansion in next-generation sequencing. Total second-quarter revenue rose 11% ye

Detailed price information for Neogenomics Inc (NEO-Q) from The Globe and Mail including charting and trades.

Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) will be announcing earnings results this Tuesday afternoon. Here’s what you need to know.

FORT MYERS, Fla., July 20, 2026--NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS

NeoGenomics (NEO) drew fresh attention after announcing PTEN IHC CDx, an FDA approved companion diagnostic that helps identify prostate cancer patients who may be eligible for AstraZeneca’s targeted therapy TRUQAP. See our latest analysis for NeoGenomics. The FDA-cleared PTEN IHC CDx arrives at a time when NeoGenomics’ share price has shown strong short term momentum, with a 30-day share price return of 40.75% and a 1-year total shareholder return of 134.13%, although the 3- and 5-year total...

NeoGenomics stock has delivered a strong 134.1% return over the past year, yet its current checks suggest the shares may be priced at a premium rather than standing out as a clear bargain. Over the last 1 year, NeoGenomics has returned 134.1%, which puts extra focus on whether the recent enthusiasm is already reflected in the price. The launch of the FDA approved PTEN IHC companion diagnostic for prostate cancer can support expectations for NeoGenomics' testing volumes and commercial reach,...

Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) jumped 3.4% in the afternoon session after the company announced the launch of the first FDA-approved immunohistochemistry (IHC) companion diagnostic test for patients with prostate cancer.

FORT MYERS, Fla., July 07, 2026--NeoGenomics will report its second quarter 2026 financial results after the close of U.S. financial markets on Tuesday, July 28, 2026.